top of page



Strong growth in the recombinant AAV (rAAV)-based gene therapy sector is creating a need for dramatically increased production of rAAV vectors. Physically increasing manufacturing capacity is neither sufficient or cost-effective.

Meet Dr Lisa Prendergast and Dr Ruth McDermott on the day to learn how Lonza has further improved its suspension HEK293 based platform with engineered plasmids. These afford significantly higher titers and productivity levels compared to standard systems. These technologies have now been incorporated in Xcite™ AAV, our suspension rAAV manufacturing platform and it is now available to take to your labs.

For more details, click here -

bottom of page